The active ingredient tirzepatide targets both GLP-1 and GIP receptors, and Eli Lilly said it remains confident in the differentiated benefits of tirzepatide, the first and only dual GIP/GLP-1 receptor agonist approved to treat adults with obesity and adults with type two diabetes, as reported by BNN Bloomberg .
Instead, communicate the timing and severity of shedding, review the pace of weight loss and nutritional tolerance, and allow the treating clinician to determine whether any dose modification is medically appropriate
doi:10.1080/09513590.2019.1576622
DOI: 10.1038/s44360-026-00108-y Cite This Page : ScienceDaily
Gut (2009) 58:9907
Medical Weight Loss Designed for Long-Term Success At Chronos Body Health & Wellness, weve helped over 10,000 patients safely lose weight with physician-supervised GLP-1 programs using medications like Ozempic, Wegovy, Mounjaro, Zepbound, and compounded alternatives when appropriate